Envisioning the Future of Early Anticancer Drug Development

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2010 Jun 11

PMID 20535131

Citations 98

Authors

Timothy A Yap

Shahneen K Sandhu

Paul Workman

Johann S de Bono

Affiliations

Soon will be listed here.

Abstract

The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

Citing Articles

Beta-blocker use and breast cancer outcomes: a meta-analysis.

Scott O, TinTin S, Cavadino A, Elwood J Breast Cancer Res Treat. 2024; 206(3):443-463.

PMID: 38837086 PMC: 11208256. DOI: 10.1007/s10549-024-07263-4.

Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma.

Ma Y, Luo F, Zhang Y, Liu Q, Xue J, Huang Y Cell Rep Med. 2024; 5(2):101414.

PMID: 38330942 PMC: 10897605. DOI: 10.1016/j.xcrm.2024.101414.

Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors.

Tan Y, Song Q Heliyon. 2024; 10(2):e24452.

PMID: 38293546 PMC: 10826821. DOI: 10.1016/j.heliyon.2024.e24452.

Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.

Stuart D, Guzman-Perez A, Brooijmans N, Jackson E, Kryukov G, Friedman A Cancer Discov. 2023; 13(10):2131-2149.

PMID: 37712571 PMC: 10551669. DOI: 10.1158/2159-8290.CD-23-0280.

New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells.

Que Z, Tian J Cancer Cell Int. 2022; 22(1):356.

PMID: 36376934 PMC: 9664634. DOI: 10.1186/s12935-022-02782-w.

References

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

DiMasi J, Feldman L, Seckler A, Wilson A . Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010; 87(3):272-7. DOI: 10.1038/clpt.2009.295. View

Seymour L, Ivy S, Sargent D, Spriggs D, Baker L, Rubinstein L . The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010; 16(6):1764-9. PMC: 2840069. DOI: 10.1158/1078-0432.CCR-09-3287. View

Mandrekar S, Sargent D . Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009; 27(24):4027-34. PMC: 2734400. DOI: 10.1200/JCO.2009.22.3701. View

Iorns E, Lord C, Turner N, Ashworth A . Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007; 6(7):556-68. DOI: 10.1038/nrd2355. View

Tan D, Thomas G, Garrett M, Banerji U, de Bono J, Kaye S . Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009; 15(5):406-20. DOI: 10.1097/PPO.0b013e3181bd0445. View

Hodgson D, Wellings R, Orr M, McCormack R, Malone M, Board R . Circulating tumour-derived predictive biomarkers in oncology. Drug Discov Today. 2010; 15(3-4):98-101. DOI: 10.1016/j.drudis.2009.12.006. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

10.

Hoering A, LeBlanc M, Crowley J . Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res. 2008; 14(14):4358-67. PMC: 2569946. DOI: 10.1158/1078-0432.CCR-08-0288. View

11.

Verweij J, Eskens F, de Jonge M . The multi-institutional phase I study: disadvantages without advantages?. J Clin Oncol. 2008; 26(12):1915-6. DOI: 10.1200/JCO.2007.15.7099. View

12.

Workman P . Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther. 2003; 2(2):131-8. View

13.

Simon R . The use of genomics in clinical trial design. Clin Cancer Res. 2008; 14(19):5984-93. DOI: 10.1158/1078-0432.CCR-07-4531. View

14.

Parulekar W, Eisenhauer E . Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst. 2004; 96(13):990-7. DOI: 10.1093/jnci/djh182. View

15.

Cannistra S . Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol. 2008; 26(22):3665-7. DOI: 10.1200/JCO.2008.17.2676. View

16.

Booth C, Calvert A, Giaccone G, Lobbezoo M, Seymour L, Eisenhauer E . Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer. 2007; 44(1):19-24. DOI: 10.1016/j.ejca.2007.07.034. View

17.

Yap T, Carden C, Kaye S . Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9(3):167-81. DOI: 10.1038/nrc2583. View

18.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

19.

Propper D, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J . Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol. 2003; 21(2):203-10. DOI: 10.1200/JCO.2003.02.008. View

20.

Yap T, Vidal L, Adam J, Stephens P, Spicer J, Shaw H . Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010; 28(25):3965-72. DOI: 10.1200/JCO.2009.26.7278. View